Low Uptake of Human Papillomavirus Vaccine Among Postpartum Women, 2006–2012 by Kilfoyle, Kimberly A. et al.
Low Uptake of Human Papillomavirus Vaccine
Among Postpartum Women, 2006–2012
Kimberly A. Kilfoyle, MD, MScR,1,* Lisa Rahangdale, MD, MPH,1 and Stacie B. Dusetzina, PhD2–5
Abstract
Background: Young adult women find it acceptable to be offered the human papillomavirus (HPV) vaccine
postpartum. Little is known about the practice of administering the HPV vaccine during the postpartum period.
Materials and Methods: The Truven Health Analytics MarketScan Commercial Claims and Encounters database
was used to develop a cohort of privately insured 18 to 26–year-old women with uncomplicated live-born preg-
nancies. Eligibility required no previous doses of HPV vaccine before delivery and continuous insurance enroll-
ment from June 2006 through 1 year postpartum. Descriptive statistics were performed.
Results: A total of 51,913 women meet age and enrollment criteria, with 3912 (7.5%) having received any
doses of vaccine before their delivery, leaving 48,001 women in this cohort. In the year postpartum, 861 women
(1.8%) received any HPV vaccine. Of the women initiating the vaccine, only 337 (39%) completed the three-
vaccine series. Women who received the vaccine, compared with women who did not, were younger (21 vs. 23
years old), more often the dependent to the insurance beneficiary (56% vs. 30%), and were more likely to have
had an abnormal pap smear in the year prior (19.6% vs. 9.1%) or postdelivery (16.4% vs. 4.9). More women
completed the HPV vaccine series when initiated within 2 months postpartum compared with women initiating
the vaccine series >2 months postpartum (44% vs. 38%).
Conclusions: Postpartum women are eligible for the HPV vaccine, yet very few are receiving it. The post-
partum period is a missed opportunity for administration of this cancer-preventing vaccine.
Introduction
In June 2006, the first human papillomavirus (HPV) vac-cine was approved by the United States Food and Drug
Administration (FDA) for the prevention of conditions caused
byHPV types 6, 11, 16, and 18. Since that time, two other HPV
vaccines have been released, which protect against infection
with up to seven high-risk, or oncogenic HPV strains de-
pending on the vaccine. If not already exposed to these virus
types, the vaccine is 97%–99% effective in preventing high-
grade precancerous cervical lesions.1 In countries, where
HPV vaccine uptake has been brisk and comprehensive, there
have been decreased rates of high-risk HPV infections, ab-
normal pap smears, and high-grade cervical dysplasia or pre-
cursors of cervical cancer.2
In the United States, the rates of HPV vaccine initiation
and completion are low. The Advisory Committee on Im-
munization Practices (ACIP) recommends vaccination of
adolescents age 11–12 with a catch up period for females
during the ages of 13–26.3 Despite recommendations, in a
2013 nationwide survey of 2077 women aged 19–26 years
of age, only 37% reported previously receiving at least
one HPV vaccine.4 Of the vaccinated women, almost half
(43.5%) received it as young adults (18–26 years of age)4—
highlighting the importance of the catch-up period as an
opportunity for vaccination. Inadequate knowledge about
HPV and the HPV vaccine is a significant barrier to HPV
vaccination in young adult women and physician recom-
mendation alone can have a significant effect on vaccine
intention and uptake.5–12
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Prenatal care is a time when women are in frequent contact
with healthcare providers, appropriately aged women are re-
ceiving cervical cancer screening, and the flu and tetanus,
diphtheria, and pertussis (TDaP) vaccines are recommended and
administered.13,14 Although theHPVvaccine is not administered
during pregnancy, it is safe to administer during the postpartum
period and while breastfeeding. For women who have not pre-
viously received the HPV vaccine, the postpartum period may
present an opportunity to vaccinate. Two studies have shown
that women find it acceptable to be offered the HPV vaccine
postpartum15,16 and the majority of those who are interested
(95%) initiate the vaccine.16 The extent towhich eligible women
are initiating HPV vaccination postpartum is unknown. Our
objective is to estimate the proportion of vaccine-eligiblewomen
who initiate the HPV vaccine in the first year postpartum among
a cohort of commercially insured women to evaluate potential
missed opportunities for vaccination among women interacting
with the healthcare system.
Materials and Methods
We used the Truven Health Analytics MarketScan Com-
mercial Claims and Encounters database from 2005 to 2013.
Data include monthly enrollment, inpatient, outpatient, and
pharmacy service claims for over 50 million employees and
their dependents. From this data we identified women ages 18–
26 with inpatient services for uncomplicated live-born preg-
nancies delivered as a result of vaginal delivery or cesarean
section (including multiples) from June 2006 to Dec 2012 (see
Supplementary Appendix for codes; Supplementary Data are
available online at www.liebertpub.com/jwh). The assigned
delivery date was the service date of the last record for a live
delivery. Among these women, we identified those who were
continuously enrolled in a health insurance plan for 1 year
before delivery and between June 2006 (the date when the HPV
vaccine was introduced) and 1 year following their delivery
date (n= 51,913). Women with evidence of HPV vaccination
before delivery (healthcare common procedure classification
codes: 90649 or 90650) were excluded (n= 3912). After all
exclusions, there were 48,001 women eligible for analyses.
Measures
The outcome of interest was uptake of HPV vaccine during
the year postpartum. We considered whether a woman had any
HPV vaccine use (HPCS codes 90649 or 90650) and comple-
tion of the three vaccine sequence within 1 year of initiation
among women who used the vaccine. Covariates included
patient age, region (west, south, northeast, north central), re-
lationship to plan holder (employee, spouse, or dependent of
the insured), and the type of health as well as plan (health
maintenance organization [HMO], preferred provider organi-
zation [PPO], or other) characteristics. Clinical characteristics
of interest measured in the year before delivery included the
presence of an abnormal pap smear, HPV diagnosis (any type
and high-risk types), and cervical dysplasia. We also evaluated
these outcomes in the postpartum year as well as general in-
teractions with outpatient care and postpartum visit receipt.
Analysis
We estimate the proportion of women using the vaccine by
year among all vaccine-eligible women. We describe the
characteristics of women at their delivery date and compare
health services utilization across subgroups of women based
on their vaccine status (no vaccine, any vaccine receipt, and
completion of three doses of vaccine). We used t-tests and
chi-squared tests for continuous and categorical variable
comparisons, respectively.
Results
Eight hundred sixty-one women (1.8% of women eligible)
received any doses of HPV vaccine in the year postpartum
and 337 women (39% of those who initiated the series and
0.7% of the total women eligible) completed the three-
vaccine series. The rate of uptake of the HPV vaccine in the
postpartum year from 2006 to 2012 was unchanged over time
(Fig. 1).
Demographic characteristics of the cohort are included in
Table 1. The average age of women in the cohort was 23
years old. Half resided in the south, with 27% in the north
central United States and 16.7% in the west. Only 5%were in
the northeast, consistent with the MarketScan Commercial
Claims coverage. Sixty-five percent of women were part of a
PPO and the others were divided equally between HMOs and
other insurance coverage types.
The 861 women who received any doses of the HPV
vaccine postpartum were younger ( p < 0.001), with an aver-
age age of 21.7 years, than women who received no doses of
vaccine. Forty percent of women who received any doses of
the HPV vaccine postpartum, as compared with 19% in the
entire cohort, were <21 years old ( p < 0.001). Fifty-six per-
cent of those receiving the vaccine were children or depen-
dents of the health insurance primary beneficiary as opposed
to 30% in the group of women who did not receive any
vaccine ( p < 0.001). Although statistically significant, dis-
tribution across region and insurance plan between the groups
of women receiving and not receiving the vaccine were
similar. Characteristics of women receiving three vaccines
(n= 337) did not vary significantly from those of women who
received only one dose of the vaccine (data not shown).
Three quarters of women in the entire cohort had cervical
cancer screening with a pap smear before delivery (Table 2).
Women who had a history of HPV vaccination in the year
postpartum were more likely than those without vaccination
FIG. 1. Percentage of women initiating the HPV vaccine
in the year postpartum by year of delivery. Note: 2006 starts
with June 2006, the time at which the HPV vaccine became
available. HPV, human papillomavirus.
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Table 1. Cohort Demographics: Postpartum Women Without Any Prior Human Papillomavirus
Vaccine Dose Aged 18–26 at Time of Delivery, MarketScan 2006–2013 (N = 48,001)
No vaccine
in postpartum year
Receipt of any HPV vaccine
in the year postpartum p
Total No., n, (row %) 47,140 (98.2) 861 (1.8)
Age at delivery <0.001
Mean (SD) 23.4 (2.55) 21.7 (2.66)
IQR
Min., max. 18–26 18–26
Median (25th–75th percentile) 24 (21–26) 21 (19–24)
Age at delivery, n (%) <0.001
<21 8637 (18.3) 340 (39.5)
21+ 38,503 (81.7) 521 (60.5)
Region, n (%) 0.018
Northeast 2284 (4.9) 52 (6.0)
North Central 12,845 (27.3) 204 (23.7)
South 24,003 (50.9) 432 (50.2)
West 7851 (16.7) 171 (19.9)
Unknown 157 (0.3) 2 (0.2)
Relationship of patient to employee, n (%) <0.001
Employee 18,309 (38.8) 260 (30.2)
Spouse 15,161 (32.2) 123 (14.3)
Child/other 13,670 (29.0) 478 (55.5)
Plan type, n (%) <0.001
HMO 7790 (16.5) 188 (21.8)
PPO 30,548 (64.8) 506 (58.8)
Other/unknown 8802 (18.7) 167 (19.4)
HMO, health maintenance organization; HPV, human papillomavirus; IQR, interquartile range; PPO, preferred provider organization;
SD, standard deviation.
Table 2. Selected Cohort Characteristics: Postpartum Women Without Any Prior Human
Papillomavirus Vaccine Use Aged 18–26 at Time of Delivery, MarketScan 2006–2013 (N= 48,001)
No vaccine
in the year
postpartum, n (%)
Receipt of any doses
of HPV vaccine
in the year
postpartum, n (%) p
Total No. 47,140 861
Outpatient claims—year before delivery
Any pap smear before delivery 36,161 (76.7) 702 (81.5) <0.001
Abnormal pap smear 4293 (9.1) 169 (19.6) <0.001
HPV diagnosis
Any cervical HPV diagnosis 549 (1.2) 20 (2.3) 0.002
Cervical high risk HPV DNA 320 (0.7) 16 (1.9) <0.001
Diagnosis of cervical dysplasia 975 (2.1) 39 (4.5) <0.001
Procedures for cervical dysplasia
Colposcopy 2342 (5.0) 107 (12.4) <0.001
Other proceduresa 190 (0.4) 8 (0.9) 0.017
Outpatient claims—postpartum year
New diagnosis of abnormal pap smear in postpartum year 2321 (4.9) 141 (16.4) <0.001
New diagnosis of HPV in postpartum year
Any cervical HPV diagnosis 533 (1.1) 55 (6.4) <0.001
Cervical high risk HPV DNA 361 (0.8) 45 (5.2) <0.001
New diagnosis of cervical dysplasia in postpartum year 1005 (2.1) 95 (11.0) <0.001
Attend any outpatient visit in postpartum year
Attend postpartum visit 32,761 (69.5) 705 (81.9) <0.001
Any other outpatient visit 14,379 (30.5) 156 (18.1) <0.001
aOther procedures include: electro/thermal cautery of cervix, cryotherapy, laser ablation, loop electrode excisional procedure (LEEP), and
cold-knife cone excision.
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to have had a pap smear in the year before delivery (81.5% vs.
76.7%, p < 0.001). The women who were vaccinated were
more than twice as likely as those who were not vaccinated to
have history of an abnormal pap smear in the year before
delivery (19.6% vs. 9.1%, p < 0.001) and to have had a di-
agnosis of any HPV type (2.3% vs. 1.2%, p = 0.002).
In the postpartum year, there were a total of 2462 new
cases of abnormal pap smears and 588 new diagnoses of
HPV. The women who received the HPV vaccine were more
likely to have a new diagnosis of an abnormal pap smear
postpartum (16.4% vs. 4.9%, p < 0.001) or new diagnosis of
HPV (6.4% vs. 1.1%, p < 0.001) compared with women who
did not receive the HPV vaccine. The number of women who
completed the three-vaccine series is small, but similar (data
not shown).
Seventy percent of women attended a postpartum visit
with their obstetrical care provider (Table 2). The group of
women receiving the HPV vaccine postpartum had slightly
higher attendance rates at the postpartum visit (83%), but
fewer other outpatient visit types compared with women not
receiving the vaccine ( p < 0.001).
The median number of days from delivery to first dose of
vaccine among those receiving the vaccine was 150 days
(range: 3–365 days) or *5 months after delivery. Of those
completing the vaccine within a year of the first dose, the
median number of days to completion was 188 (range: 61–
360 days). Eighty percent of women initiated the vaccine
after 60 days. There was a higher rate of completion of the
three-vaccine series if the vaccine was initiated within the
first 60 days postpartum, although this was not statistically
significant. Forty-four percent of women who initiated the
vaccine within 60 days of delivery completed the three-
vaccine series compared with 38% of women who initiated
the vaccine after 60 days ( p = 0.160).
Discussion
Based on our data of young adult women in this large
commercially insured cohort, very few eligible women re-
ceived the HPV vaccine in the year postpartum, <2%. Just
over 1/3 of those women initiating the series completed all
three vaccines. Compared with women who did not receive
the vaccine postpartum, women who were vaccinated were
younger and more likely to have already had HPV exposure
as demonstrated by higher rates of abnormal pap smears,
HPV diagnoses, and resultant procedures before delivery and
in the year postpartum.
Young adult women are among those most at risk of ac-
quiring HPV infection.17 The ACIP recommends the HPV
vaccine during adolescence because it is most efficacious if it
is administered before the onset of sexual activity and ex-
posure to the vaccine-type HPV strains.18 Additionally, ad-
olescents have a more robust immune response to the vaccine
than when received as an adult.18 However, because the
majority of adolescents are incompletely vaccinated,19 it
becomes important to promote uptake and completion of the
HPV vaccine during the catch-up period.
Despite being sexually active, the majority of young adult
women will not have acquired any of the oncogenic HPV
subtypes.20 In our cohort, 14.4% of the population had an
abnormal pap and 2.4% had abnormal HPV testing. Women
who received the HPV vaccine postpartum were more likely
to have had an abnormal pap smear. This may reflect that
abnormal testing motivated provider recommendation for
vaccination or individuals with abnormal testing were more
accepting of the vaccine. Regardless, it is equally important
to vaccinate women who have not had abnormal testing.
These may be women who have not had prior exposure to
vaccine-type HPV strains and would receive full benefit from
vaccination.
Prenatal care providers are missing opportunities to ad-
minister this cancer-preventing vaccine. Currently, there are
no clinical guidelines recommending the vaccine postpartum.
If indicated, cervical cancer screening is performed early in
pregnancy. This is a time when women should also be
screened for previous receipt of the HPV vaccine. Provider
recommendation for HPV vaccination is associated with in-
creased vaccination7,12 and prior research suggests that wo-
men find it acceptable to be offered and receive the HPV
vaccine postpartum.15,16 For any pregnant woman who has
not received the vaccine before pregnancy, administration
postpartum should be recommended and offered.
In our study, 77% of women had cervical cancer screening
in the year before delivery and *70% of women attended a
postpartum visit. Fewer than 20% of the women who received
any vaccine received the first dose in the 2 months postpartum,
which suggests that it was not received at a postpartum visit.
Our data suggest that prenatal care providers are not utilizing
the opportunity to offer the HPV vaccine during pregnancy and
administer the HPV vaccine postpartum.
In a recent study, only 36.9% of young adult women report
receiving one or more doses of HPV vaccine.21 In contrast,
only 8.6% of women in the current study received the vaccine
before delivery. Seeing oneself as low risk for HPV acqui-
sition is a perceived barrier to receiving the vaccine by both
patients and providers.5,10,22 In our study, women who did
not receive the vaccine were more likely to be the spouse of
the primary insurance beneficiary compared with the women
who did receive the vaccine and, therefore, may have con-
sidered themselves low risk for HPV because they were
married. Recommendation for vaccination is universal re-
gardless of relationship status. Thus, pregnant women should
not be excluded from consideration for the vaccine because
they have already been sexually active or may be in a mo-
nogamous relationship.
Additional barriers to HPV vaccination include lack of
knowledge about HPV, not having the vaccine offered by a
provider, concern over safety and side effects of the vaccine,
cost, and ability to make it to three vaccine visits.5,6,9,11 Al-
though these barriers cannot be evaluated in administrative
data, it is interesting to note that insurance coverage expan-
sion in 2010 appears to have had no impact on uptake among
these women, although its intended effect is to reduce cost-
related barriers to use. As of 2010, the Affordable Care Act
mandated coverage of ACIP-approved vaccines at no cost for
insured patients, and this includes coverage of the HPV
vaccine.
Using a large claims-based database allowed us to look at
what, unfortunately, was a rare outcome in this population—
HPV vaccination. There are several important limitations to
note. First, to ensure that women had not been previously
vaccinated we required that they have continuous health plan
enrollment from the time of vaccine availability through
1 year postpartum resulting in a large sample size loss. If
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women received vaccines outside of their insurance, this
would not be captured, although this is unlikely given the cost
of the vaccine. Next, this database is made up exclusively of
privately insured individuals, the majority from the South,
and therefore represents a specific demographic and is not
generalizable to all patients. Further research should look at
practice patterns for HPV vaccination in populations that are
uninsured or Medicaid insured. Finally, we were not able to
evaluate reasons why women were not vaccinated postpar-
tum and this requires further study.
We must improve processes and promote awareness to
identify women eligible for HPV vaccination at the time of
pregnancy and plan for vaccination postpartum. Examples of
this include educating providers and other staff within offices
on the appropriate use of the HPV vaccine, using the elec-
tronic medical record for prompts regarding vaccination,
developing reminder systems for protocols to include HPV
vaccine recommendation and administration, initiating pa-
tients, and developing novel ways for patients to access all
three doses of the vaccine.12,23,24 It would be worthwhile to
determine if uptake of the vaccine was improved if women
could access the vaccine more conveniently, for example, at a
pediatrician’s office or a pharmacy. Finally, cutting the cost
of the vaccine for women without coverage could signifi-
cantly improve uptake.24
Results from our study indicate that very few young adult
women receive the HPV vaccine in the year postpartum.
Prenatal and postpartum visits thus represent missed clinical
opportunities to discuss HPV vaccination and, in the post-
partum period, to administer the HPV vaccine.25 While we
would agree that vaccination in adolescence is best, clearly a
large percentage of young adult women remain unvaccinated
and would benefit from the vaccine. The postpartum period
could be an ideal time to reach and vaccinate these women.
We hope that by highlighting the missed opportunity to ad-
minister the HPV vaccine postpartum, practice patterns for
screening, recommendation and administration of the HPV
vaccine around the time of pregnancy will improve.
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